Project

Addition of Darolutamide to first line treatment of mCRPC: a randomized open label phase II trial.

Ongoing - recruitment active · 2024 until 2028

Type
Clinical Studies
Range
Multicentric, KSSG as main centre
Units
Status
Ongoing - recruitment active
Start Date
2024
End Date
2028
Financing
Industry
Labels
prostate cancer
Brief description/objective